Evofem Presents Results of Phexxi in P-III (AMPOWER) Clinical Trial for the Prevention of Pregnancy at ACOG 2022
Shots:
- The P-III (AMPOWER) trial evaluates the efficacy & safety of Phexxi in patients for the prevention of pregnancy
- The results showed that patients achieved a fewer UTIs than the general population, 77 (5.8%) in Phexxi vs 11% in the general population experienced an on-study UTI from the 1339 women self-administered 1 dose of Phexxi and were included in the safety population & 1 woman experienced an event classified as urinary tract bacterial inf. & remaining 76 had events classified as urinary tract inf.
- The study continues to show a larger & positive impact on woman's sexual, reproductive & general health. The results from the P-III (EVOGUARD) trial of Phexxi for chlamydia & gonorrhea are expected in 2022
Ref: PRNewswire | Image: Evofem
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
